Travere is seeing an increase in value due to positive data on their competitor Filspari from Novartis and their acquisition of Calliditas.
Read More: https://seekingalpha.com/news/4110827-travere-stock-gains-novartis-data-calliditas-buyout?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news